Reviva (RVPH) CEO receives 150,075 stock option grants under 2020 plan

Q: What did RVPH President and CEO Laxminarayan Bhat report on this Form 4?

He reported two stock option awards under Reviva’s 2020 Equity Incentive Plan. The grants provide rights to acquire a total of 150,075 shares of common stock at a fixed exercise price, with specified vesting schedules and a long-dated expiration in 2036.

Q: How many stock options were granted to the RVPH CEO and his spouse?

The filing shows 150,075 stock options in total. Bhat received 109,150 options held directly, while 40,925 options are held indirectly through his spouse. Each grant has its own immediate and time-based vesting structure tied to the 2020 Equity Incentive Plan.

Q: What is the exercise price and expiration date of the RVPH CEO’s options?

Both grants have an exercise price of $1.87 per share , based on Reviva’s common stock closing price on the March 18, 2026 grant date. The options expire on March 17, 2036, giving a 10-year term consistent with typical equity incentive awards.

Q: Were these RVPH CEO transactions open-market purchases or sales of stock?

No, the Form 4 shows grant or award acquisitions of stock options, coded “A.” These are compensation-related option grants, not open-market buying or selling of existing shares. No purchase or sale price is reported, only the option exercise price and vesting terms.

Q: How are the spouse-held RVPH options treated in the Form 4 filing?

The 40,925-share option grant is reported as indirect ownership “By Spouse” . It vests with the same immediate and monthly schedule and the same $1.87 exercise price and 2036 expiration. The filing attributes these options as indirectly owned through the spouse.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.

One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bhat Laxminarayan

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	109,150	$0.00	--
Grant/Award	Stock Option (right to buy)	40,925	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 109,150 shares (Direct); Stock Option (right to buy) — 40,925 shares (Indirect, By Spouse)

Footnotes (1)

This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan. This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/20/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bhat Laxminarayan

(Last)

(First)

(Middle)

C/O REVIVA PHARMACEUTICALS HOLDINGS, INC

10080 N. WOLFE RD., SUITE SW3-200

(Street)

CUPERTINO

CALIFORNIA

95014

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REVIVA PHARMACEUTICALS HOLDINGS, INC. [ RVPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.87	03/18/2026		A⁽¹⁾		109,150		⁽¹⁾	03/17/2036	Common Stock, par value $0.0001 per share	109,150	$0	109,150	D
Stock Option (right to buy)	$1.87	03/18/2026		A⁽²⁾		40,925		⁽²⁾	03/17/2036	Common Stock, par value $0.0001 per share	40,925	$0	40,925	I	By Spouse

Explanation of Responses:

1. This option award was made on March 18, 2026 (the "Grant Date") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

2. This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan.

	/s/ Narayan Prabhu, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did RVPH President and CEO Laxminarayan Bhat report on this Form 4?

He reported two stock option awards under Reviva’s 2020 Equity Incentive Plan. The grants provide rights to acquire a total of 150,075 shares of common stock at a fixed exercise price, with specified vesting schedules and a long-dated expiration in 2036.

How many stock options were granted to the RVPH CEO and his spouse?

The filing shows 150,075 stock options in total. Bhat received 109,150 options held directly, while 40,925 options are held indirectly through his spouse. Each grant has its own immediate and time-based vesting structure tied to the 2020 Equity Incentive Plan.

What are the vesting terms of the RVPH CEO’s new option awards?

For the 109,150-share grant, 34,110 options vest immediately and 75,040 vest monthly from April 2026 to December 2028. For the 40,925-share spouse-held grant, 12,789 vest immediately and 28,136 vest monthly over the same period, all under the 2020 Equity Incentive Plan.

What is the exercise price and expiration date of the RVPH CEO’s options?

Both grants have an exercise price of $1.87 per share, based on Reviva’s common stock closing price on the March 18, 2026 grant date. The options expire on March 17, 2036, giving a 10-year term consistent with typical equity incentive awards.

Were these RVPH CEO transactions open-market purchases or sales of stock?

No, the Form 4 shows grant or award acquisitions of stock options, coded “A.” These are compensation-related option grants, not open-market buying or selling of existing shares. No purchase or sale price is reported, only the option exercise price and vesting terms.

How are the spouse-held RVPH options treated in the Form 4 filing?

The 40,925-share option grant is reported as indirect ownership “By Spouse”. It vests with the same immediate and monthly schedule and the same $1.87 exercise price and 2036 expiration. The filing attributes these options as indirectly owned through the spouse.